Disagreeing with two of his colleagues in the Eastern District of Pennsylvania, a federal judge has ruled that GlaxoSmithKline is based in Delaware, which means that drug products liability litigation against the company will remain in federal court.
The company’s decisions are made in its Wilmington, Del., office, making that place of business its “nerve center,” according to U.S. District Judge Paul Diamond of the Eastern District of Pennsylvania.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
